Daniel Mulreany

Title: The Innovative Contributions of Daniel Mulreany

Introduction

Daniel Mulreany is a notable inventor based in San Francisco, CA. He has made significant strides in the field of medical treatments, particularly focusing on cholangiocarcinoma, a rare and aggressive form of cancer. His work is characterized by a commitment to advancing therapeutic options for patients facing this challenging diagnosis.

Latest Patents

Daniel Mulreany holds a patent for "Methods of treating cholangiocarcinoma." This patent outlines methods for treating advanced or metastatic cholangiocarcinoma in patients by administering infigratinib or a pharmaceutically acceptable salt thereof. This treatment is particularly relevant for patients who have experienced progression of the disease after previous therapies. His innovative approach aims to provide new hope for those affected by this difficult condition. He has 1 patent to his name.

Career Highlights

Mulreany is currently associated with QED Therapeutics, Inc., where he continues to contribute to the development of groundbreaking treatments. His work at the company reflects a dedication to improving patient outcomes through innovative research and development.

Collaborations

Throughout his career, Daniel has collaborated with talented professionals in the field, including Riccardo Panicucci and Michael Monteith. These collaborations have fostered an environment of innovation and shared knowledge, further enhancing the impact of their collective work.

Conclusion

Daniel Mulreany's contributions to the field of cancer treatment exemplify the importance of innovation in medicine. His patent for treating cholangiocarcinoma represents a significant advancement in therapeutic options for patients. Through his work at QED Therapeutics, Inc., he continues to push the boundaries of medical research and improve the lives of those affected by cancer.